康哲药业:INHBE小核酸药物CMS-D008临床试验获批治疗超重或肥胖

财经网
Mar 06

近日,康哲药业发布公告称,其自主研发的创新药INHBE小核酸药物CMS-D008于2026年3月4日获得中国国家药品监督管理局签发的药物临床试验批准通知书。该药物将用于超重或肥胖的临床试验。CMS-D008是一款皮下注射的siRNA药物,旨在通过靶向抑制肝脏的抑制素亚基βE基因表达,从而降低脂质堆积。全球超重和肥胖成年人的比例预计到2030年将达到50%,这为CMS-D008的市场前景提供了良好的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10